SurModics (SRDX) Tops Q4 EPS by 8c, Revenues Beat; FY19 EPS Mid-Point Below Consensus, FY18 Revenue Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Surmodics Reports Fourth Quarter Fiscal 2018 Results and Issues Fiscal 2019 Guidance
November 9, 2018 7:30 AM ESTEDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 fourth quarter ended September 30, 2018, and provided its financial outlook for fiscal 2019.
Summary of Fourth Quarter Fiscal 2018 Highlights and Fiscal 2019 Guidance
Revenue of $23.0 million, an increase of 15% year-over-year GAAP EPS of ($0.13), non-GAAP EPS of $0.05 Submitted application for first in-human study for arteriovenous (AV) access drug coated balloon (DCB) Fiscal... More